Read by QxMD icon Read

Breast Cancer Research and Treatment

Michelle I Silver, William Klein, Goli Samimi, Lori Minasian, Jennifer Loud, Megan C Roberts
PURPOSE: To evaluate factors associated with compliance to the National Comprehensive Cancer Network (NCCN) guidelines for BRCA1/2 testing and identify groups who are at risk of under- and over-use of BRCA1/2 testing. METHODS: Data included 20,758 women from Dr. Susan Love Research Foundation's The Health of Women (HOW) Study® . Multinomial logistic regression was used to examine the association of socioeconomic and demographic characteristics with whether the woman was over-, under-, or appropriately tested for BRCA1/2 mutations, per 2015 NCCN guidelines...
November 9, 2018: Breast Cancer Research and Treatment
Britt I Drögemöller, Galen E B Wright, Joanne Shih, Jose G Monzon, Karen A Gelmon, Colin J D Ross, Ursula Amstutz, Bruce C Carleton
PURPOSE: Tamoxifen is one of the principal treatments for estrogen receptor (ER)-positive breast cancer. Unfortunately, between 30 and 50% of patients receiving this hormonal therapy relapse. Since CYP2D6 genetic variants have been reported to play an important role in survival outcomes after treatment with tamoxifen, this study sought to summarize and critically appraise the available scientific evidence on this topic. METHODS: A systematic literature review was conducted to identify studies investigating associations between CYP2D6 genetic variation and survival outcomes after tamoxifen treatment...
November 8, 2018: Breast Cancer Research and Treatment
Daniela L Buscariollo, Angel M Cronin, Nancy A Borstelmann, Rinaa S Punglia
PURPOSE: To examine whether pre-diagnosis patient-reported health-related quality of life (HRQOL) and depressive symptoms are associated with local treatment for older women with ductal carcinoma in situ (DCIS) and stage I breast cancer (BC). METHODS: Using the SEER-MHOS dataset, we identified women ≥ 65 years old with DCIS or stage I BC diagnosed 1998-2011 who completed surveys ≤ 24 months before diagnosis. Depressive symptoms were measured by major depressive disorder (MDD) risk and HRQOL was measured by Physical and Mental Component Summary scores (PCS and MCS, respectively) of the SF-36/VR-12...
November 8, 2018: Breast Cancer Research and Treatment
Abdi T Gudina, Glenn Copeland, Amr S Soliman, Kelly A Hirko
PURPOSE: While racial disparities in inflammatory breast cancer (IBC) incidence are fairly well documented, with black women having significantly higher rates compared to white women; less is known about whether IBC prognosis differs by race/ethnicity. Therefore, the objective of this study was to assess racial/ethnic disparities in survival among women diagnosed with IBC in the Michigan Cancer Surveillance Program (MCSP) from 1998 to 2014. METHODS: We examined the frequency and percentage of breast cancer cases coded to the various IBC codes in the MCSP registry over the study period...
November 7, 2018: Breast Cancer Research and Treatment
Sarah J Skuli, Jennifer Y Sheng, Elissa T Bantug, Nelli Zafman, Carol Riley, Jessica M Ruck, Katherine C Smith, Claire F Snyder, Karen L Smith, Vered Stearns, Antonio C Wolff
PURPOSE: Breast cancer survivors face numerous challenges after diagnosis and treatment. Several models have been developed to attempt to improve quality of care. Here, we describe characteristics and outcomes of patients who participated in survivorship visits (SV) at Johns Hopkins (JH). METHODS: We retrospectively reviewed charts of breast cancer patients who participated in an optional SV 1-3 months after completing locoregional therapy and initial systemic therapy...
November 7, 2018: Breast Cancer Research and Treatment
Cong Xue, Wenwen Wei, Peng Sun, Wei Zheng, Xiaoju Diao, Fei Xu, Jiajia Huang, Xin An, Wen Xia, Ruoxi Hong, Kuikui Jiang, Riqing Huang, Zhongyu Yuan, Shusen Wang, Anhua Li, Ruhai Zou, Yanxia Shi
PURPOSE: Ovarian function is important for optimizing endocrine treatment in patients with hormone receptor-positive (HR+) early breast cancer (eBC). The aim of the study was to determine whether patients' pretreatment levels of anti-Mullerian hormone (AMH) were associated with menses status after chemotherapy and to build a predictive nomogram model for amenorrhea in women with HR+ eBC. METHODS: Between August 2013 and December 2014, 120 premenopausal patients with HR+ eBC were included retrospectively...
November 3, 2018: Breast Cancer Research and Treatment
Ethan J Hoppe, Lala R Hussain, Kevin J Grannan, Erik M Dunki-Jacobs, David Y Lee, Barbara A Wexelman
PURPOSE: Prior research demonstrates racial disparities in breast cancer treatment. Disparities are commonly attributed to more advanced stage at presentation or aggressive tumor biology. We seek to evaluate if racial disparities persist in the treatment of stage 1 breast cancer patients who by definition are not delayed in presentation. METHODS: We selected stage 1 breast cases in the National Cancer Data Base. Patients were divided into two cohorts based on race and included White and Black patients...
November 3, 2018: Breast Cancer Research and Treatment
Ting Li, Juan Yang, Yinghua Lv, Fang Yin, Ling Xu, Hongxia Liu, Qingshan Zheng, Lujin Li
OBJECTIVE: This study aimed to quantitatively evaluate drug efficacy and identify relevant factors that affect the relief of hot flashes in patients with breast cancer. METHODS: A comprehensive literature search was performed using public databases. Randomized clinical studies on drug therapy for the treatment of hot flashes in patients with breast cancer were identified. A time-effect model was established, and crucial pharmacodynamic parameters, such as maximal efficacy (Emax ) and onset time (ET50 ), were used to reflect the differences in efficacy among the drugs...
November 2, 2018: Breast Cancer Research and Treatment
Sungmin Park, Byung In Moon, Se Jeong Oh, Han-Byoel Lee, Min-Ki Seong, Seokwon Lee, Kyung Do Byun, Seung Pil Jung, Soo Youn Bae
PURPOSE: We explored the association between parity and the risk of developing a specific subtype of breast cancer. We also assessed the association between parity and prognosis according to subtypes. METHODS: A total of 158,189 patients were enrolled in the Korean Breast Cancer Society Registry database between 1996 and 2015 in Korea. The database provided information on sex, age, number of parity, surgical method, stage, histological findings, presence of biologic markers, adjuvant therapy, and date and cause of death...
November 2, 2018: Breast Cancer Research and Treatment
Yujing J Heng, Jun Wang, Thomas U Ahearn, Susan B Brown, Xuehong Zhang, Christine B Ambrosone, Victor Piana de Andrade, Adam M Brufsky, Fergus J Couch, Tari A King, Francesmary Modugno, Celine M Vachon, Natalie C DuPre, Montserrat Garcia-Closas, Melissa A Troester, David J Hunter, A Heather Eliassen, Rulla M Tamimi, Susan E Hankinson, Andrew H Beck
PURPOSE: In post-menopausal women, high body mass index (BMI) is an established breast cancer risk factor and is associated with worse breast cancer prognosis. We assessed the associations between BMI and gene expression of both breast tumor and adjacent tissue in estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) diseases to help elucidate the mechanisms linking obesity with breast cancer biology in 519 post-menopausal women from the Nurses' Health Study (NHS) and NHSII...
November 1, 2018: Breast Cancer Research and Treatment
Sue P Heiney, Pearman D Parker, Tisha M Felder, Swann Arp Adams, Omonefe O Omofuma, Jennifer M Hulett
PURPOSE: Adherence to endocrine therapy for hormone positive breast cancer is a significant problem, especially in minority populations. Further, endocrine therapy reduces recurrence and thus mortality. However, little data are available on interventions to improve adherence. The authors conducted a systematic review to examine the impact of interventions, strategies, or approaches aimed to improve endocrine therapy adherence among women with breast cancer. A secondary aim was to determine if interventions had any cultural modifications...
November 1, 2018: Breast Cancer Research and Treatment
Małgorzata Szostakowska, Alicja Trębińska-Stryjewska, Ewa Anna Grzybowska, Anna Fabisiewicz
INTRODUCTION: The majority of breast cancers (BCs) are characterized by the expression of estrogen receptor alpha (ERα+). ERα acts as ligand-dependent transcription factor for genes associated with cell survival, proliferation, and tumor growth. Thus, blocking the estrogen agonist effect on ERα is the main strategy in the treatment of ERα+ BCs. However, despite the development of targeted anti-estrogen therapies for ER+ BC, around 30-50% of early breast cancer patients will relapse...
November 1, 2018: Breast Cancer Research and Treatment
Tae In Yoon, Beom Seok Kwak, On Vox Yi, Seonok Kim, Eunhae Um, Keong Won Yun, Hae-Na Shin, SaeByul Lee, Guiyun Sohn, Il Yong Chung, Jisun Kim, Beom Seok Ko, Jong Won Lee, Byung Ho Son, Sei Hyun Ahn, Hee Jeong Kim
PURPOSE: Contralateral prophylactic mastectomy is increasing, despite unclear evidence of improving survival. To investigate the age-related risk factors for contralateral breast cancer (CBC). METHODS: This study included 8716 patients diagnosed with non-metastatic unilateral invasive breast cancer between 1989 and 2008. Data on primary tumor size, node metastasis, grade and subtype using individual matching were used to adjust for differences in the primary tumor and treatment between younger and older age groups...
October 30, 2018: Breast Cancer Research and Treatment
Sonia Vallet, Fengjuan Fan, Stefano Malvestiti, Martin Pecherstorfer, Martin Sattler, Andreas Schneeweiss, Henning Schulze-Bergkamen, Joseph T Opferman, Michael H Cardone, Dirk Jäger, Klaus Podar
PURPOSE: Recent studies have emphasized a key role for the anti-apoptotic Bcl-2 family member Mcl-1 in conferring tumor cell survival and drug resistance in breast cancer (BC). Mcl-1 inhibitors, such as the BH3-mimetic EU-5346, therefore represent an exciting new class of targeting agents and are a current focus of widespread cancer-drug development efforts. METHODS: ONCOMINE analysis was utilized to compare expression profiles of Bcl-2 family members across all major BC subgroups...
October 29, 2018: Breast Cancer Research and Treatment
Sylvie Rodrigues-Ferreira, Anne Nehlig, Clarisse Monchecourt, Sarah Nasr, Laetitia Fuhrmann, Magali Lacroix-Triki, Ingrid Garberis, Véronique Scott, Suzette Delaloge, Barbara Pistilli, Philippe Vielh, Thierry Dubois, Anne Vincent-Salomon, Fabrice André, Clara Nahmias
PURPOSE: The identification of molecular biomarkers for classification of breast cancer is needed to better stratify the patients and guide therapeutic decisions. The aim of this study was to investigate the value of MAPRE1 gene encoding microtubule-end binding proteins EB1 as a biomarker in breast cancer and evaluate whether combinatorial expression of MAPRE1 and MTUS1 gene encoding EB1-negative regulator ATIP3 may improve breast cancer diagnosis and prognosis. METHODS: Probeset intensities for MAPRE1 and MTUS1 genes were retrieved from Exonhit splice array analyses of 45 benign and 120 malignant breast tumors for diagnostic purposes...
October 27, 2018: Breast Cancer Research and Treatment
Shang Cao, Jinyi Zhou, Zheng Zhu, Feiran Wei, Wei Li, Shurong Lu, Jian Su, Hao Yu, Wencong Du, Lan Cui, Pingmin Wei, Ming Wu
PURPOSE: The accumulating evidence indicates that weight gain in adulthood is more predictive of breast cancer risk than absolute body weight. However, the relative impact of timing of weight gain in adulthood on breast cancer as well as other characteristics of the association between weight and breast cancer has not been well documented. METHODS: This population-based case-control study of breast cancer included 818 patients with newly diagnosed primary breast cancer and 935 residence and age-matched healthy controls...
October 27, 2018: Breast Cancer Research and Treatment
Katherine R Walter, Marvella E Ford, Mathew J Gregoski, Rita M Kramer, Kendrea D Knight, Laura Spruill, Lourdes M Nogueira, Bradley A Krisanits, Van Phan, Amanda C La Rue, Michael B Lilly, Stefan Ambs, King Chan, Tonya F Turner, Heidi Varner, Shweta Singh, Jaime Uribarri, Elizabeth Garrett-Mayer, Kent E Armeson, Ebony J Hilton, Mark J Clair, Marian H Taylor, Andrea M Abbott, Victoria J Findlay, Lindsay L Peterson, Gayenell Magwood, David P Turner
PURPOSE: Lifestyle factors associated with personal behavior can alter tumor-associated biological pathways and thereby increase cancer risk, growth, and disease recurrence. Advanced glycation end products (AGEs) are reactive metabolites produced endogenously as a by-product of normal metabolism. A Western lifestyle also promotes AGE accumulation in the body which is associated with disease phenotypes through modification of the genome, protein crosslinking/dysfunction, and aberrant cell signaling...
October 27, 2018: Breast Cancer Research and Treatment
Laura W Bowers, Claire G Lineberger, Nikki A Ford, Emily L Rossi, Arunima Punjala, Kristina K Camp, Bruce K Kimler, Carol J Fabian, Stephen D Hursting
PURPOSE: Exposure to the polyphenolic plant lignan secoisolariciresinol diglucoside (SDG) and its metabolite enterolactone (ENL) has been associated with reduced breast cancer progression, particularly for estrogen receptor alpha (ERα)-negative disease, and decreased preclinical mammary tumor growth. However, while preclinical studies have established that SDG and ENL affect measures of progression in models of triple-negative breast cancer (TNBC, a subset of ERα-negative disease), the molecular mechanisms underlying these effects remain unclear...
October 26, 2018: Breast Cancer Research and Treatment
Gertraud Maskarinec, Yurii B Shvetsov, Shannon M Conroy, Christopher A Haiman, Veronica W Setiawan, Loïc Le Marchand
PURPOSE: The purpose of the study was to investigate the association of type 2 diabetes (T2D) with survival of breast cancer (BC) patients across five ethnic groups within the Multiethnic Cohort study. METHODS: Between recruitment in 1993-1996 and 2013, 7570 incident BC cases were identified through SEER cancer registries in Hawaii and California. T2D diagnosed before BC was ascertained in 1013 women from self-reports and confirmed by administrative data sources...
October 26, 2018: Breast Cancer Research and Treatment
Guang-Yu Liu, Jian-Wei Li, Wen-Jia Zuo, Diana Ivanova, Xiao-Qing Jia, Li Lei
PURPOSE: This study was designed to determine the safety and clinical efficacy of metronomic chemotherapy combined with aromatase inhibitors (AIs) for hormone receptor (HR)-positive advanced breast cancer (ABC) patients who cannot tolerate conventional-dose chemotherapy. METHODS: Postmenopausal patients with HR-positive ABC, who exhibited disease progression after first-line AIs treatment and who could not tolerate or rejected conventional chemotherapy, were enrolled in this study...
October 25, 2018: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"